This proposal studies how dormant cancer cells that have disseminated to secondary organs avoid the immune response and how the immune system keeps them in check. Uncovering the involved mechanisms and preclinical evaluation of immunotherapies will reveal therapeutic opportunities for the minimal residual disease, which results in relapse of lethal metastatic diseases that account for the majority of patient deaths.
|Effective start/end date||3/1/21 → 2/28/23|
- National Cancer Institute: $84,709.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.